2. UroToday Home
  3. Conference Highlights
  4. ASCO 2021
  5. ASCO 2021 Prostate Cancer

ASCO 2021

ASCO 2021: Differences in the Tumor Genomic Landscape Between African Americans (AA) and Caucasians (CA) Advanced Prostate Cancer (aPC) Patients (Pts) by Comprehensive Genomic Profiling (CGP) of Cell-Free DNA (cfDNA)

(UroToday.com) Disparities in prostate cancer incidence and outcomes between African American and Caucasian men in the United States have been well documented. While many of the differences in outcomes are attributable to health system disparities (as evidence by equivalent outcomes when patients are treated in equal access models), emerging data suggest potential differences in the tumor genomic profile of African American and Caucasian men with advanced prostate cancer. In the Prostate, Testicular, Penile Poster session at the 2021 American Society of Clinical Oncology 2021 Annual Meeting, Dr. Pedro Barata presented their analysis of the tumor genomic landscape of African American and Caucasian men with prostate cancer, using cfDNA comprehensive genomic profiling.


To do some, the authors identified men with advanced prostate cancer who had available cfDNA comprehensive genomic profiling utilizing the Guardant (G360) 73 gene panel from six academic centres. In addition to the G360 73 gene panel, the G360 74 gene panel was used to identify CDK12 mutation (as this is not detected in the 73 gene panel) in an independent cohort of patients with advanced prostate cancer. The authors used Barnard’s test to evaluate the association between genetic mutation and gene and a Bayesian Network (BN) machine learning approach to compare the genomic landscape.

ASCO_Bayesnet.png



In total, the authors included 552 patients (of whom, 125 were African American and 427 were Caucasian) who had available results for the G360 73 gene panel. Numerous genomic aberrations were more common in African American patients, as seen in the following table.

ASCO_genomic_aberrations.png



Particularly actionable alterations included BRCA2 (5.3%), BRCA1 (0.9%), ATM (3.4%), PIK3A/mTOR/AKT (16.8%), and PTEN (5.8%).

In the independent cohort of 261 patients with advanced prostate cancer who were tested with the G360 74 gene panel (of whom 106 were African American and 155 were Caucasian), CDK12 mutations were significantly more common in African American patients. (9.4% vs. 1.9%, p=0.006). These findings were supported by machine learning analysis.

The authors conclude that, while these data are hypothesis-generating and require external validation, they suggested that differences in the tumor genomic profile between African American and Caucasian patients with advanced prostate cancer may allow for a molecularly targeted treatment approach which will improve treatment outcomes.

Presented by: Pedro C. Barata, MD, MSc, Assistant Professor of Medicine, Hematology & Medical Oncology, Tulane University, New Orleans, Louisiana

Written by: Christopher J.D. Wallis, Urologic Oncology Fellow, Vanderbilt University Medical Center Contact: @WallisCJD on Twitter at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Virtual Annual Meeting #ASCO21, June, 4-8, 2021